A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor Adherence

The recruitment status of this study is unknown because the information has not been verified recently.

Verified January 2011 by Progenics Pharmaceuticals, Inc..
Recruitment status was Recruiting

Sponsor:

Information provided by:

Progenics Pharmaceuticals, Inc.

ClinicalTrials.gov Identifier:

NCT01272258

First received: January 5, 2011

Last updated: January 6, 2011

Last verified: January 2011

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study is currently recruiting participants.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	No date given